Compare APPN & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APPN | GLPG |
|---|---|---|
| Founded | 1999 | 1999 |
| Country | United States | Belgium |
| Employees | N/A | 452 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.9B |
| IPO Year | 2017 | N/A |
| Metric | APPN | GLPG |
|---|---|---|
| Price | $23.47 | $27.73 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 2 |
| Target Price | $29.80 | ★ $36.50 |
| AVG Volume (30 Days) | ★ 927.0K | 118.1K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 101.59 | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $226,743,000.00 | N/A |
| Revenue This Year | $13.79 | N/A |
| Revenue Next Year | $10.56 | N/A |
| P/E Ratio | $1,156.50 | ★ N/A |
| Revenue Growth | ★ 28.29 | N/A |
| 52 Week Low | $19.79 | $24.74 |
| 52 Week High | $46.06 | $37.78 |
| Indicator | APPN | GLPG |
|---|---|---|
| Relative Strength Index (RSI) | 56.32 | 36.68 |
| Support Level | $22.39 | $27.73 |
| Resistance Level | $25.22 | $34.04 |
| Average True Range (ATR) | 1.24 | 0.56 |
| MACD | 0.35 | 0.08 |
| Stochastic Oscillator | 79.10 | 26.20 |
Appian Corp is a low-code enterprise platform-as-a-service company focusing on business process management. The company's Appian platform is an integrated automation platform providing tools for organizations to design, automate, and optimize end-to-end processes and complex business operations. The company also provides maintenance and support as well as consulting services and training related to its platform. The majority of its revenue is subscription-based with the remainder from services, with much of its subscription revenue being derived from its cloud-based platform. Geographically, the company derives maximum revenue from its Domestic operations, and also has its presence Internationally.
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, and it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.